KIRKLAND – Pfizer Canada ULC announced that Health Canada has approved PADCEV® (enfortumab vedotin) an antibody-drug conjugate (ADC) in combination with pembrolizumab, a PD-1 inhibitor, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (la/mUC) with no prior systemic therapy for mUC. The approval was made under the Health Canada Priority Review process, after having met the …